GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Universal Ibogaine Inc (TSXV:IBO) » Definitions » Capex-to-Revenue

Universal Ibogaine (TSXV:IBO) Capex-to-Revenue : 0.04 (As of Apr. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Universal Ibogaine Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Universal Ibogaine's Capital Expenditure for the three months ended in Apr. 2024 was C$-0.02 Mil. Its Revenue for the three months ended in Apr. 2024 was C$0.54 Mil.

Hence, Universal Ibogaine's Capex-to-Revenue for the three months ended in Apr. 2024 was 0.04.


Universal Ibogaine Capex-to-Revenue Historical Data

The historical data trend for Universal Ibogaine's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Universal Ibogaine Capex-to-Revenue Chart

Universal Ibogaine Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Jul22 Jul23
Capex-to-Revenue
Get a 7-Day Free Trial - - - 0.09 0.35

Universal Ibogaine Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.03 0.05 0.02 0.04

Competitive Comparison of Universal Ibogaine's Capex-to-Revenue

For the Biotechnology subindustry, Universal Ibogaine's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Universal Ibogaine's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Universal Ibogaine's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Universal Ibogaine's Capex-to-Revenue falls into.



Universal Ibogaine Capex-to-Revenue Calculation

Universal Ibogaine's Capex-to-Revenue for the fiscal year that ended in Jul. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.36) / 1.03
=0.35

Universal Ibogaine's Capex-to-Revenue for the quarter that ended in Apr. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.019) / 0.537
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Universal Ibogaine  (TSXV:IBO) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Universal Ibogaine Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Universal Ibogaine's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Universal Ibogaine Business Description

Traded in Other Exchanges
Address
815 8th Avenue South West, Suite 600, Calgary, AB, CAN, T2P 3P2
Universal Ibogaine Inc develops a platform of addiction treatment clinics, which use ibogaine as a primary modality for the interruption and ideally cessation of addictions to primarily opioids such as oxycodone, heroin, fentanyl, as well as alcohol, cocaine, and other stimulants. It runs addiction clinics it has a research partner clinic in Mexico.
Executives
Ian Rabb Senior Officer

Universal Ibogaine Headlines